A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.

@article{Boulenger2012ARC,
  title={A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.},
  author={J. P. Boulenger and Henrik Loft and Ioana Florea},
  journal={Journal of psychopharmacology},
  year={2012},
  volume={26 11},
  pages={1408-16}
}
The efficacy and tolerability of Lu AA21004 in the prevention of relapse of major depressive disorder (MDD) in patients in remission after acute treatment was evaluated. Patients (n=639) aged 18-75 years with a primary diagnosis of MDD with a current major depressive episode (MDE) ≥4 weeks' duration, at least one prior MDE and a MADRS total score ≥26 received 12-week, open-label Lu AA21004 at 5 or 10mg/day. Patients in remission (MADRS ≤10) at both weeks 10 and 12 were assigned to double-blind… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…